Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: J Clin Lipidol. 2009;3(3):167–178. doi: 10.1016/j.jacl.2009.04.052

Table 3.

Descriptions of Flushing Reported (% of Subjects)

3A. Any flushing in the past 4 weeks
Atorvastatin/Niacin (n=19)
Niacin/Atorvastatin (n=17)
Study Visit: Niacin Dose Yes Niacin Dose Yes



4 0 - 500 29
5 0 - 1000 59
6 0 - 1500 47
7 500 47 1500 41
8 1000 47 1500 59
9 1500 68 1500 41
3B. Most frequent level of flushing
Severity: 1 2 3 4 5 6 1 2 3 4 5 6
Study Visit:
4 - - - - - - 0 18 0 6 6 0
5 - - - - - - 6 6 18 12 12 6
6 - - - - - - 0 12 6 18 12 0
7 5 16 5 5 16 0 6 18 6 12 0 0
8 0 5 16 21 5 0 6 29 6 12 6 0
9 5 11 21 11 21 0 12 24 6 0 0 0
3C. Strongest flushing feeling
Severity: 1 2 3 4 5 6 1 2 3 4 5 6
Study Visit:
4 - - - - - - 0 6 12 0 12 0
5 - - - - - - 0 6 12 18 6 0
6 - - - - - - 0 12 0 12 18 6
7 5 5 0 11 26 0 0 18 6 6 12 0
8 0 5 11 21 11 0 0 29 0 12 24 0
9 5 11 11 16 21 5 6 18 6 12 0 0
3D. Actions related to flushing
Action: Consider Decrease Decrease Took ASA ASA Helped Consider Decrease Decrease Took ASA ASA Helped
Study Visit:
4 - - - - 0 0 6 6
5 - - - - 0 0 18 18
6 - - - - 18 0 24 24
7 0 0 5 5 0 0 18 18
8 11 5 11 11 0 0 29 18
9 11 0 21 16 0 0 18 18

Severity:

1 – Tingle

2 – Warm, few minutes

3 – Warm, red, 15 minutes

4 – Warm, red, 30 minutes

5 – Hot, flushed, 31–60 minutes

6 – Intense, > 60 minutes